Story
Latigo Biotherapeutics Shares Surge Over 14% in Public Market Debut

Shares of Latigo Biotherapeutics (NASDAQ: LTGO) surged more than 14% in the company's public market debut on Friday. The stock was trading at $20.53 in early market activity, according to a report from Zhitong Finance.
Focus on Non-Opioid Pain Relief
Latigo Biotherapeutics is a clinical-stage company focused on developing non-addictive alternatives to opioid-based painkillers. Its pipeline is aimed at addressing a significant unmet need for effective pain management without the risk of dependency.
The company's lead drug candidate, LTG-001, is an oral medication being developed for the treatment of moderate-to-severe acute pain, including post-operative pain. The goal is to provide a level of pain relief comparable to opioids while avoiding their well-documented addictive properties.
AdScientific Approach
LTG-001 functions as a selective inhibitor of the Nav1.8 sodium ion channel. This specific mechanism is key to its safety profile.
- The Nav1.8 channel is primarily expressed in peripheral pain-sensing neurons.
- By targeting these peripheral neurons, the drug is designed to block pain signals without acting on the central nervous system.
- This approach is intended to prevent the potential for addiction that is characteristic of opioid medications, which directly affect the brain.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.